158001-28-6

Basic information

• Product Name: 5-AMINO-1-(T-BUTYL)PYRAZOLE-4-CARBONITRILE
• Synonyms: 5-AMINO-1-(TERT-BUTYL)PYRAZOLE-4-CARBONITRILE;5-Amino-1-(tert-butyl);BUTTPARK 51\09-68;5-AMINO-1-(T-BUTYL)PYRAZOLE-4-CARBONITRILE
• CAS NO: 158001-28-6
• Molecular Formula: C₈H₁₂N₄
• Molecular Weight: 164.21
• Mol File: 158001-28-6.mol

Chemical Properties

• Melting Point: 92.9-94.5℃
• Boiling Point: 325.7 °C at 760 mmHg
• Flash Point: 150.8 °C
• Appearance: /
• Density: 1.13 g/cm³
• Vapor Pressure: 0.000226mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.56±0.10(Predicted)
• CAS DataBase Reference: 5-AMINO-1-(T-BUTYL)PYRAZOLE-4-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-1-(T-BUTYL)PYRAZOLE-4-CARBONITRILE(158001-28-6)
• EPA Substance Registry System: 5-AMINO-1-(T-BUTYL)PYRAZOLE-4-CARBONITRILE(158001-28-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 158001-28-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Amino-1-(t-butyl)pyrazole-4-carbonitrile is used as a key intermediate in the synthesis of various pharmaceuticals. Its molecular structure contributes to the development of new drugs, enhancing the therapeutic potential of medications and broadening the scope of treatment options available.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Amino-1-(t-butyl)pyrazole-4-carbonitrile serves as an essential intermediate for the synthesis of crop protection products. Its incorporation into these products aids in the development of more effective and targeted agrochemicals, thereby improving agricultural yields and crop protection.
Used as a Building Block in Organic Synthesis:
5-Amino-1-(t-butyl)pyrazole-4-carbonitrile is utilized as a versatile building block in the preparation of other organic compounds. Its structural attributes make it a crucial component in the synthesis of a wide range of chemical entities, further expanding its applications across various industries.

InChI:InChI=1/C8H12N4/c1-8(2,3)12-7(10)6(4-9)5-11-12/h5H,10H2,1-3H3

Upstream product

• 7400-27-3 tertbutylhydrazine hydrochloride 
• 123-06-8 Ethoxymethylenemalononitrile 
• 32064-67-8 tert-butylhydrazine 

Downstream Products

• 1151650-34-8 1-(tert-butyl)-3-(3,5-difluorophenoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1151650-52-0 1-(tert-butyl)-3-(3-(trifluoromethyl)phenoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1151650-43-9 3-(3-bromophenoxy)-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1151650-28-0 1-(tert-butyl)-3-(3-methoxyphenoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1151650-25-7 1-(tert-butyl)-3-(m-tolyloxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1151650-35-9 C₁₅H₁₅ClFN₅O 
• 862728-60-7 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1151650-24-6 1-(tert-butyl)-3-(3-chlorophenoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 221244-07-1 1-(tert-butyl)-3-(4-(tert-butyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 956025-63-1 4-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzonitrile 
• 221243-82-9 1-(tert-butyl)-3-(1-naphthyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1135429-05-8 1-tert-butyl-3-(4-vinylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 338391-69-8 1-tert-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant articles and documents

PET/CT tracer agent with selectivity to different lung cancer cells as well as preparation method and application of PET/CT tracer agent

The invention provides a PET/CT tracer agent with selectivity to different lung cancer cells as well as a preparation method and application of the PET/CT tracer agent. The PET/CT tracer agent is a compound represented by a formula I shown in the specification, or a salt or stereoisomer of the compound, wherein R1 and R2 are respectively and independently selected from H or C1-C5 alkyl; and X is independently selected from C, F, F, O or N. The F-PET/CT tracer agent prepared by the method can be selectively taken in by the different carcinogenic driving gene mutant lungcancer cells; test results show that the F-PET/CT tracer agent is expected to be imaged in an NRas Q61K tumor model in a high-quality manner and has certain selectivity for the different carcinogenic driving gene mutant lung cancers, and different from any non-specific F-FDG which can cause high-concentration imaging when glucose metabolism is increased, the tracer agent is expected to make up for the deficiency of imaging by singly using the F-FDG; therefore, the F-PET/CT tracer agent provided by the invention is expected to be applied to PET/CT iconography, and changes the situation of lack of tracer agents on lung cancer.

Three-dimensional network structure crystal with high porosity and preparation method thereof

The invention provides a crystal of a compound 1; the crystal is a monoclinic system, and the space group is P 121/n; the cell parameters of the crystal comprise that a is equal to 5.8499+/-0.0018 angstroms, b is equal to 10.622+/-0.004 angstroms, c is eq

Compounds with anti-inflammatory effect, and preparation method and application thereof

The invention provides compounds as shown in a formula I which is described in the description, or salts thereof. Experimental results show that the compounds provided by the invention, specifically acompound 7 and a compound 9, can effectively inhibit the release level of an inflammatory factor IL-6; and the compound 9 can inhibit the protein level of phosphorylated NF-kB p65, the protein levelof phosphorylated Akt, the protein level of phosphorylated STAT3 and the protein level of an adhesion molecule ICAM-1. The compounds provided by the invention have good application prospect in preparation of drugs used for treating inflammatory diseases.

Crystal with porous supramolecular structure and preparation method thereof (by machine translation)

The invention provides a crystal of a [3,4 - d] pyrazolopyrimidine compound, wherein [3,4 - d] the crystal is a pyrazolopyrimidine compound and a super-molecule hydrate formed by water molecules [3,4 - d] 9 7. Experimental results show that the novel porous supramolecular 7 framework structure 9 containing a plurality of water channels is formed by the compound of the present invention, and in particular 9, the compound of the present invention has a very good application prospect in the fields of artificial channel materials, drug carriers and porous materials 7 9 IL - 6 9 NF - κ B p65 Akt STAT3 ICAM - 1. (by machine translation)

Supermacrocyclic Assemblies by Hydrogen-Bond Codes of C7-Phenol Pyrazolo and Pyrrolo Derivatives of Adenine

Hydrogen bond (HB) mediated base pair motifs are versatile scaffolds of diverse supramolecular constructs. Here, we report that two new four- and six-membered supermacrocyclic assemblies with intriguing geometries could self-assemble from two new adenine derivatives, APN (1) and APC (2). The conversion of a conventional HB acceptor, N8 of 1, to a non-conventional HB donor, C8?H of 2, had a pronounced impact on the overall intricate HB network and self-assembly patterns, epitomizing the subtleties in design and exploitation of such base-pair motifs as promising tectons for building supramolecular architectures.

Discovery of a potent protein kinase D inhibitor: insights in the binding mode of pyrazolo[3,4-d]pyrimidine analogues

In this study, we set out to rationally optimize PKD inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. The lead compound for this study was 1-NM-PP1, which was previously found by us and others to inhibit PKD. In our screening we identified one compound (3-IN-PP1) displaying a 10-fold increase in potency over 1-NM-PP1, opening new possibilities for specific protein kinase inhibitors for kinases that show sensitivity towards pyrazolo[3,4-d]pyrimidine derived compounds. Interestingly the observed SAR was not in complete agreement with the commonly observed binding mode where the pyrazolo[3,4-d]pyrimidine compounds are bound in a similar fashion as PKD's natural ligand ATP. Therefore we suggest an alternate binding mode where the compounds are flipped 180 degrees. This possible alternate binding mode for pyrazolo[3,4-d]pyrimidine based compounds could pave the way for a new class of specific protein kinase inhibitors for kinases sensitive towards pyrazolo[3,4-d]pyrmidines.

PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of t

COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES

Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases.

Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii

Calcium dependent protein kinase 1 (CDPK1) is an essential enzyme in the opportunistic pathogen Toxoplasma gondii. CDPK1 controls multiple processes that are critical to the intracellular replicative cycle of T. gondii including secretion of adhesins, motility, invasion, and egress. Remarkably, CDPK1 contains a small glycine gatekeeper residue in the ATP binding pocket making it sensitive to ATP-competitive inhibitors with bulky substituents that complement this expanded binding pocket. Here we explored structure-activity relationships of a series of pyrazolopyrimidine inhibitors of CDPK1 with the goal of increasing selectivity over host enzymes, improving antiparasite potency, and improving metabolic stability. The resulting lead compound 24 exhibited excellent enzyme inhibition and selectivity for CDPK1 and potently inhibited parasite growth in vitro. Compound 24 was also effective at treating acute toxoplasmosis in the mouse, reducing dissemination to the central nervous system, and decreasing reactivation of chronic infection in severely immunocompromised mice. These findings provide proof of concept for the development of small molecule inhibitors of CDPK1 for treatment of CNS toxoplasmosis.

Pyrazolo[3,4-d]pyrimidine derivative

The invention discloses a pyrazolo[3,4-d]pyrimidine derivative shown as formula (I). The pyrazolo[3,4-d]pyrimidine derivative as a compound has an obvious inhibition effect on tumour cells, can be used for preventing and/or treating tumor related diseases, especially lung cancer, and has a wide application prospect. The formula (I) is shown in the description.